Lac La Biche shoreline gets health check - CBC

EdmontonBiologists are revisiting Lac La Biche's shoreline a decade after a previous assessment to track changes in development and environmental conditions. Biologists revisit the shoreline to see how development and environmental changes have affected the lakeJessica Campbell · CBC News · Posted: Oct 01, 2026 7:00 AM EDT | Last Updated: October 1Listen to this articleEstimated 4 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. A section of Lac La Biche's shoreline which is being studied by Masse Environmental as part of a shoreline study. They are looking at how much development is on the shoreline and how much of the area is undeveloped as one part of the research. (Jessica Campbell/CBC)From a boat on Lac La Biche, a team of biologists is getting a closer look at what has changed along the lake's shoreline over the past decade. Masse Environmental was contracted by Living Lakes Canada, a community-based water-monitoring nonprofit, to repeat a study first conducted 10 years ago.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.

The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.